Axsome Inks Agreement To Obtain Exclusive Global Rights To TAK-063 From Takeda

Axsome Therapeutics entered an asset purchase agreement to obtain exclusive global rights to TAK-063 (balipodect), an oral selective PDE10A inhibitor. No financial terms or timelines were disclosed; the deal meaningfully expands Axsome's CNS pipeline but remains speculative until clinical/regulatory progress or commercial plans are announced.

Analysis

Axsome Therapeutics entered an asset purchase agreement to obtain exclusive global rights to TAK-063 (balipodect), an oral selective PDE10A inhibitor. No financial terms or timelines were disclosed; the deal meaningfully expands Axsome's CNS pipeline but remains speculative until clinical/regulatory progress or commercial plans are announced.